Related Experiment Videos
Validating the performance of the mammary sentinel lymph node team
David M Euhus1, George N Peters, A Marilyn Leitch
1Division of Surgical Oncology, U.T. Southwestern Medical Center, Dallas, Texas 75390-9155, USA. david.euhus@UTSouthwestern.edu
Journal of Surgical Oncology
|March 29, 2002
Summary
Establishing standardized performance measures for the mammary sentinel lymph node (SLN) procedure is crucial for accurate breast cancer staging. Approximately 30 procedures per surgeon are needed to achieve optimal SLN visualization and identification rates, ensuring improved patient outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Cancer Research
Background:
- The mammary sentinel lymph node (SLN) procedure offers improved accuracy and reduced morbidity for axillary staging in breast cancer.
- Institutional experience significantly impacts SLN procedure outcomes, necessitating standardized performance measures for widespread adoption of SLN biopsy alone.
Purpose of the Study:
- To establish standardized performance criteria and benchmarks for the mammary SLN procedure.
- To determine the learning curve and number of cases required for surgeons to achieve optimal performance in SLN biopsy.
Main Methods:
- Prospective data collection for the initial 156 mammary SLN procedures performed by three surgeons.
- Analysis of SLN visualization rates, identification rates, metastasis detection, and false negative rates.
Main Results:
- An SLN visualization rate exceeding 80% on lymphoscintigraphy required approximately 75 cases.
- Surgeons achieved consistent SLN identification rates of over 90% in the operating room after 15-25 cases.
- The metastasis detection rate increased over time, and the overall false negative rate was 5%.
Conclusions:
- Suggested performance benchmarks include: SLN visualization rate ≥80%, SLN identification rate ≥90%, and a false negative rate of 5%.
- Approximately 30 procedures per surgeon were sufficient to meet these established benchmarks.
- Standardization of performance is key to optimizing the transition to sentinel lymph node biopsy-only management in breast cancer care.